

Page 11, line 19: insert --(SEQ ID No. 3)-- after "1".

Page 20, line 16: substitute --abnormality-- for "abnormmaly".

Page 21, line 31: substitute --syndrome-- for "syndrom".

Page 39, line 25: insert --(SEQ ID Nos. 2 and 4)-- after "1".

Page 39, line 33: insert --(SEQ ID No. 3)-- after "1".

Page 41, line 1: insert --(SEQ ID No. 5)-- after "3".

Page 41, line 4: insert --(SEQ ID No. 6)-- after "3".

Page 41, line 9: insert --(SEQ ID No. 7)-- after "3".

Page 42, line 23: insert --(SEQ ID Nos. 11 through 15)-- after "21".

Page 43, line 5: insert --(SEQ ID No. 9)-- after "variant)".

Page 43, line 6: insert --(SEQ ID No. 10)-- after "variant)".

Page 43, line 7: insert --(SEQ ID No. 8)-- after "21".

Page 43, line 14: insert --(SEQ ID No. 12)-- after "-3".

IN THE CLAIMS

Please add new claims 45 and 46 as follows:

2/26 58
45. The growth factor as claimed in claim 17, wherein the expression vector is a DNA molecule encoding a neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in Figure 1 as known as SEQ ID No. 4 or a functional equivalent, derivative or bioprecursor of said growth factor.

59
46. The growth factor as claimed in claim 17, wherein the expression vector is an antisense molecule capable of hybridizing to the DNA molecule defined in claim 45.

Please make the following changes to the claims: